MannKind Corporation - Common Stock — Quarterly Cash Flow (NASDAQ:MNKD) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 410.14 M411.7 M494.64 M792.18 M744.4 M732.3 M Total liabilities 468.76 M466.74 M539.19 M843.2 M803.6 M799.5 M Total equity -58.62 M-55.04 M-44.55 M-51.02 M-59.2 M-67.2 M Total liabilities & shareholders' equities 410.14 M411.7 M494.64 M792.18 M744.4 M732.3 M Total debt ——109.65 M354.64 M318.72 M319.08 M Net debt ——-150.38 M183.29 M184.86 M207.96 M

News

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

MannKind: New Approvals Majorly Increase MannKind's Prospects (NASDAQ:MNKD)

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF - Slideshow (NASDAQ:MNKD) 2026-07-30

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD)

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates